Patient >18 years of age
Patient presents with acute coronary syndrome (ACS) or stable coronary artery disease (CAD)
Patient is eligible for PCI
Patient is willing and able to provide informed written consent
Patient not able to receive 12 months of dual anti-platelet therapy
Failure of index PCI
Patient or physician refusal to enroll in the study
Patient with known CYP2C19 genotype prior to randomization
Planned revascularization of any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure
Anticipated discontinuation of clopidogrel or ticagrelor within the 12 month follow up period, example for elective surgery
Serum creatinine >2.5 mg/dL within 7 days of index procedure
Platelet count <80,000 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3 if persistent (at least 2 abnormal values) within 7 days prior to index procedure.
History of intracranial hemorrhage
Known hypersensitivity to clopidogrel or ticagrelor or any of its components
Patient is participating in an investigational drug or device clinical trial that has not reached its primary endpoint
Patient previously enrolled in this study
Patient is pregnant, lactating, or planning to become pregnant within 12 months
Patient has received an organ transplant or is on a waiting list for an organ transplant
Patient is receiving or scheduled to receive chemotherapy within 30 days before or after the procedure
Patient is receiving immunosuppressive therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous, etc.)
Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor)
Concomitant use of simvastatin/lovastatin > 40 mg qd
Concomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine)
Non-cardiac condition limiting life expectancy to less than one year, per physician judgment (e.g. cancer)
Known history of severe hepatic impairment
Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
Patient has an active pathological bleeding, such as active gastrointestinal (GI) bleeding
Inability to take aspirin at a dosage of 100 mg or less
Current substance abuse (e.g., alcohol, cocaine, heroin, etc.)

NCT01742117_inc_T1
Person
age
NCT01742117_inc_T2
Value
>18 years
NCT01742117_inc_T3
Condition
acute coronary syndrome
NCT01742117_inc_T4
Condition
ACS
NCT01742117_inc_T5
Condition
coronary artery disease
NCT01742117_inc_T6
Condition
CAD
NCT01742117_inc_T7
Qualifier
stable
NCT01742117_inc_T8
Procedure
PCI
NCT01742117_inc_T9
Mood
eligible
NCT01742117_inc_T11
Condition
able to receive
NCT01742117_inc_T12
Procedure
dual anti-platelet therapy
NCT01742117_inc_T13
Temporal
12 months
NCT01742117_inc_T14
Procedure
PCI
NCT01742117_inc_T15
Temporal
index
NCT01742117_inc_T16
Observation
Failure
NCT01742117_inc_T18
Condition
CYP2C19 genotype
NCT01742117_inc_T19
Temporal
prior to randomization
NCT01742117_inc_T20
Reference_point
randomization
NCT01742117_inc_T21
Procedure
revascularization
NCT01742117_inc_T22
Mood
Planned
NCT01742117_inc_T23
Qualifier
any vessel
NCT01742117_inc_T24
Temporal
within 30 days post-index procedure
NCT01742117_inc_T25
Reference_point
index procedure
NCT01742117_inc_T26
Temporal
within 12 months post-procedure
NCT01742117_inc_T27
Reference_point
procedure
NCT01742117_inc_T28
Qualifier
of the target vessel(s)
NCT01742117_inc_T29
Scope
any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure
NCT01742117_inc_T30
Drug
clopidogrel
NCT01742117_inc_T31
Drug
ticagrelor
NCT01742117_inc_T32
Temporal
within the 12 month follow up period
NCT01742117_inc_T33
Procedure
elective surgery
NCT01742117_inc_T34
Mood
example for
NCT01742117_inc_T35
Scope
clopidogrel or ticagrelo
NCT01742117_inc_T36
Measurement
Serum creatinine
NCT01742117_inc_T37
Value
>2.5 mg/dL
NCT01742117_inc_T38
Temporal
within 7 days of index procedure
NCT01742117_inc_T39
Reference_point
index procedure
NCT01742117_inc_T40
Measurement
Platelet count
NCT01742117_inc_T42
Value
<80,000 or >700,000 cells/mm3
NCT01742117_inc_T41
Measurement
white blood cell count
NCT01742117_inc_T43
Value
<3,000 cells/mm3
NCT01742117_inc_T44
Temporal
within 7 days prior to index procedure
NCT01742117_inc_T45
Reference_point
index procedure
NCT01742117_inc_T46
Scope
Platelet count <80,000 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3
NCT01742117_inc_T47
Condition
intracranial hemorrhage
NCT01742117_inc_T48
Condition
hypersensitivity
NCT01742117_inc_T49
Drug
clopidogrel
NCT01742117_inc_T50
Drug
ticagrelor
NCT01742117_inc_T51
Drug
any of its components
NCT01742117_inc_T52
Scope
clopidogrel or ticagrelor
NCT01742117_inc_T55
Condition
pregnant
NCT01742117_inc_T56
Condition
lactating
NCT01742117_inc_T57
Mood
planning to become
NCT01742117_inc_T58
Condition
pregnant
NCT01742117_inc_T59
Temporal
within 12 months
NCT01742117_inc_T60
Procedure
organ transplant
NCT01742117_inc_T61
Mood
is on a waiting list
NCT01742117_inc_T62
Procedure
organ transplant
NCT01742117_inc_T63
Procedure
chemotherapy
NCT01742117_inc_T64
Mood
is receiving
NCT01742117_inc_T65
Mood
scheduled to receive
NCT01742117_inc_T66
Scope
is receiving or scheduled to receive
NCT01742117_inc_T67
Temporal
within 30 days before or after the procedure
NCT01742117_inc_T68
Reference_point
the procedure
NCT01742117_inc_T69
Procedure
immunosuppressive therapy
NCT01742117_inc_T70
Condition
r autoimmune dise n immun
NCT01742117_inc_T71
Condition
autoimmune disease
NCT01742117_inc_T72
Condition
human immunodeficiency virus
NCT01742117_inc_T73
Condition
systemic lupus erythematous
NCT01742117_inc_T74
Scope
human immunodeficiency virus, systemic lupus erythematous
NCT01742117_inc_T75
Procedure
oral anticoagulation therapy
NCT01742117_inc_T76
Multiplier
chronic
NCT01742117_inc_T77
Drug
vitamin K antagonist
NCT01742117_inc_T78
Drug
direct thrombin inhibitor
NCT01742117_inc_T79
Drug
Factor Xa inhibitor
NCT01742117_inc_T80
Scope
vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor
NCT01742117_inc_T81
Drug
simvastatin
NCT01742117_inc_T82
Drug
lovastatin
NCT01742117_inc_T83
Multiplier
> 40 mg qd
NCT01742117_inc_T84
Temporal
Concomitant
NCT01742117_inc_T85
Drug
potent CYP3A4 inhibitors
NCT01742117_inc_T86
Drug
atazanavir
NCT01742117_inc_T87
Drug
clarithromycin
NCT01742117_inc_T88
Drug
indinavir
NCT01742117_inc_T89
Drug
itraconazole
NCT01742117_inc_T90
Drug
ketoconazole
NCT01742117_inc_T91
Drug
nefazodone
NCT01742117_inc_T92
Drug
nelfinavir
NCT01742117_inc_T93
Drug
ritonavir
NCT01742117_inc_T94
Drug
saquinavir
NCT01742117_inc_T95
Drug
telithromycin
NCT01742117_inc_T96
Drug
voriconazole
NCT01742117_inc_T97
Drug
rs (atazanavi e, dexam
NCT01742117_inc_T98
Drug
carbamazepine
NCT01742117_inc_T99
Drug
dexamethasone
NCT01742117_inc_T100
Drug
phenobarbital
NCT01742117_inc_T101
Drug
phenytoin
NCT01742117_inc_T102
Drug
rifampin
NCT01742117_inc_T103
Drug
rifapentine
NCT01742117_inc_T104
Scope
carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine
NCT01742117_inc_T105
Scope
atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole
NCT01742117_inc_T106
Temporal
Concomitant
NCT01742117_inc_T107
Condition
Non-cardiac condition
NCT01742117_inc_T108
Observation
life expectancy
NCT01742117_inc_T109
Temporal
less than one year
NCT01742117_inc_T110
Condition
hepatic impairment
NCT01742117_inc_T111
Qualifier
severe
NCT01742117_inc_T112
Condition
bleeding diathesis
NCT01742117_inc_T113
Condition
coagulopathy
NCT01742117_inc_T114
Procedure
blood transfusions
NCT01742117_inc_T115
Mood
will refuse
NCT01742117_inc_T116
Condition
pathological bleeding
NCT01742117_inc_T117
Qualifier
active
NCT01742117_inc_T118
Qualifier
active
NCT01742117_inc_T119
Condition
gastrointestinal (GI) bleeding
NCT01742117_inc_T120
Condition
Inability to take
NCT01742117_inc_T121
Drug
aspirin
NCT01742117_inc_T122
Multiplier
100 mg or less
NCT01742117_inc_T123
Condition
substance abuse